Latest News and Press Releases
GlobeNewswire specializes in the distribution and delivery of press releases, financial disclosures and multimedia content to the media and general public.
www.globenewswire.comHere are the latest developments on Samsung Bioepis based on the most recently available public information:
Overview
- Samsung Bioepis is a biosimilars-focused subsidiary of Samsung Biologics with ongoing expansion in immunology and oncology biosimilars, alongside efforts in novel drug development. This is consistent with public statements about their strategic focus and pipeline goals.[3][6][7]
Recent regulatory and pipeline updates
- In 2024–2025, Samsung Bioepis pursued regulatory pathways for several biosimilars and expanded their immunology portfolio, including programs that reference major biologics. For example, they reported progress on Phase 3 programs in immunology and a broadened pipeline targeting multiple indications.[4][5]
- In early 2025, there were reports that the broader Samsung Biologics group planned corporate restructuring to spin off Samsung Bioepis as part of a holding-company structure, aiming to clarify businesses and potentially accelerate development in biosimilars and novel therapies. This restructuring was described as intended to reduce conflicts of interest between CDMO operations and biosimilar/novel drug development activities.[2]
Pipeline and partnerships
- Samsung Bioepis and its parent entity have highlighted ambitions to secure a broad biosimilar and novel-drug portfolio by 2030, with emphasis on multiple antibody targets (including pembrolizumab in earlier stages) and expansion into additional therapeutic areas like dermatology and oncology. These statements were reiterated in industry conference dialogues and press summaries.[3]
Corporate and contact details
- The company has publicly advertised its mission to increase patient access to high-quality biologics and to grow its footprint in global biosimilars markets. Their official newsroom and corporate pages reflect ongoing activity and updates, including business milestones and pipeline progress.[6][7][9]
Notes
- Samsung Bioepis’ public communication emphasizes a strong, scalable biosimilar platform, with ongoing regulatory submissions and a widened development pipeline. For the most current specifics (e.g., exact drug candidates in late-stage trials, regulatory statuses, and live dates), I can pull the latest press releases or regulatory filings if you’d like.
Would you like me to pull the very latest press releases or summarize a specific biosimilar in Samsung Bioepis’ pipeline? I can also organize a timeline of recent regulatory milestones if that helps.